作者
JJ Swen, I Wilting, AL De Goede, L Grandia, H Mulder, DJ Touw, A De Boer, JMH Conemans, TCG Egberts, OH Klungel, R Koopmans, J Van Der Weide, B Wilffert, H‐J Guchelaar, VHM Deneer
发表日期
2008/5
期刊
Clinical pharmacology & therapeutics
卷号
83
期号
5
页码范围
781-787
简介
Despite initial enthusiasm,1,2,3 the use of pharmacogenetics has remained limited to investigation in only a few clinical fields such as oncology and psychiatry.4,5,6,7,8 The main reason is the paucity of scientific evidence to show that pharmacogenetic testing leads to improved clinical outcomes.9,10 Moreover, for most pharmacogenetic tests (such as tests for genetic variants of cytochrome P450 enzymes) a detailed knowledge of pharmacology is a prerequisite for application in clinical practice, and both physicians and pharmacists might find it difficult to interpret the clinical value of pharmacogenetic test results. Guidelines that link the result of a pharmacogenetic test to therapeutic recommendations might help to overcome these problems, but such guidelines are only sparsely available. In 2001, an early step was taken to develop such guidelines for the therapeutic use of antidepressants, and these included …
引用总数
200920102011201220132014201520162017201820192020202120222023202410111819171012211322202129232817
学术搜索中的文章
JJ Swen, I Wilting, AL De Goede, L Grandia, H Mulder… - Clinical pharmacology & therapeutics, 2008